Key Highlights
- Regeneron (NASDAQ:REGN) rose 0.58% to USD 957.76 on November 17, one of the few gainers, about 3.4% below its 52-week high.
- Third quarter Revenue rose 36% to USD 5.116 billion, and non-GAAP EPS rose 70% to USD 20.07 against USD 11.83.
- Dupixent global sales rose 35% to about USD 6.5 billion, EYLEA HD sales rose 62% to USD 699 million and Libtayo sales rose 51% to USD 550 million.
- The European Commission approved alternative Libtayo dosing on November 17, and an expanded Sanofi alliance adds USD 1.0 billion upfront.
Record Sales Across the Franchise
Regeneron reported third quarter results on October 30. Total revenues were USD 5.116 billion against USD 3.754 billion, GAAP diluted EPS was USD 18.45 against USD 13.62 and non-GAAP EPS was USD 20.07. Dupixent sales, recorded by Sanofi, rose 35% to about USD 6.5 billion, and Sanofi collaboration revenue rose 68% to USD 2.724 billion. In eye care, EYLEA HD in the United States rose 62% to USD 699 million, while the older EYLEA fell 41% to USD 400 million, so the combined Franchise was down only 1% at USD 1.099 billion. Libtayo sales rose 51% to USD 550 million, with United States sales up 81%. Praluent rose 21% to USD 81 million and Evkeeza rose 28% to USD 55 million. Chief executive Leonard S. Schleifer said Dupixent, EYLEA HD and Libtayo each achieved record net sales. GAAP Net Income rose 33% to USD 1.949 billion and non-GAAP net income rose 67% to USD 2.15 billion. Lynozyfic reached USD 19 million from USD 1 million, while Bayer collaboration revenue fell 23% to USD 267 million.
Guidance Changes and Capital Returns
Management raised its 2026 non-GAAP product gross Margin outlook to about 86% from 84% to 85%, and lowered non-GAAP selling, general and administrative expense guidance to USD 2.4 billion to USD 2.5 billion from USD 2.5 billion to USD 2.6 billion, while Research and Development guidance moved up modestly to USD 6.05 billion to USD 6.15 billion. The company repurchased USD 2.3 billion of stock in the first nine months and had about USD 2.2 billion of authorization left, and it holds about USD 18.9 billion of cash and marketable securities. The expanded Sanofi alliance adds USD 1.0 billion upfront, recognized in the fourth quarter, and up to USD 7.0 billion of milestones. The expanded alliance provides for equal sharing of development and commercialization costs. Long Term Debt was about USD 2.0 billion against cash and securities of USD 18.9 billion.
Pipeline and Regulatory Catalysts
On November 17 the European Commission approved Libtayo dosing of 700 milligrams every six weeks across six cancer indications. On November 12 the company reported Phase 2 baloncibart data in postural tachycardia syndrome, with a nominal 11.4 beats per minute reduction against placebo and a Phase 3 planned for the first half of 2027. On November 8 it reported early siRNA data in fatty liver disease, with liver fat down 58% to 80%. Other items include an extended government agreement for Inmazeb worth about USD 270 million and an FDA decision target in February 2027 for the Ordspono resubmission. The shares rose 0.58% on Tuesday, and a relative strength reading near 68 suggests healthy momentum. The company also presented ten abstracts at a major cancer meeting in October, reported zero new heterotopic ossification lesions against nine on placebo in an extension of the Pasatru trial, and showed longer term Libtayo data in which the hazard ratio for death of 0.63 was not statistically significant. Investor conference appearances are scheduled for December 1 and December 2.
Where Things Stand
Regeneron is growing across its main franchises and has added a larger Sanofi alliance. Further regulatory decisions and the 2027 outlook will decide whether the stock can set new highs.






Please wait processing your request...